Supplemental oxygen, a therapy that has been used for more than a century, is recommended in all practice guidelines in the management of hypoxemic (peripheral oxygen saturation <90% to 94% or partial arterial oxygen pressure <60 mm Hg) patients with acute heart failure, but its use in normoxemic patients is controversial. Several pre-clinical and early clinical studies have shown the detrimental effects of oxygen therapy and subsequent hyperoxia in patients with normal oxygen saturation levels. These effects are suggested to be gauged by the increased production of reactive oxygen species and the related oxidative stress and by the reductions in coronary blood flow and myocardial oxygen consumption resulting from hyperoxia-induced vasoconstriction in the cerebral, coronary, and systemic vasculature.
H eart failure (HF) is a highly prevalent chronic disease, and the majority of patients present for the first time or repetitively to the hospital through the emergency department (ED) with "acute" symptoms (1,2). Clinicians treating patients with acute heart failure (AHF) have few proven therapies at their disposal and thus rely on established clinical practice. However, many of these routine clinical practices have little evidence base beyond that of low-quality, nonrandomized evidence. Diuretic agents and oxygen are often used concurrently despite the lack of highquality evidence supporting either of these interventions. Although evidence has emerged from recent AHF trials and cohorts on the risks and potential benefits of emerging pharmacological agents, many clinical questions remain unanswered. For example, noninvasive mechanical ventilation was used widely and thought to be a potential therapy for AHF, but when it was tested in a larger randomized controlled trial (RCT), there was no additional mortality benefit over standard oxygen therapy in this strategy (3) .
However, a recent Cochrane review did show an overall benefit for noninvasive mechanical ventilation in reducing hospital mortality, endotracheal intubation, and adverse events compared with standard oxygen therapy (4).
Supplemental oxygen has been used in the management of patients with cardiac disease and investigated for more than a century (5) . The rationale for supplemental oxygen therapy in these patients was to improve oxygenation of diseased myocardial tissue. 
GUIDELINE RECOMMENDATIONS ON SUPPLEMENTAL OXYGEN THERAPY
Practice guidelines have emphasized that the symptoms of AHF should be relieved as rapidly as possible (2, 7, 8) . Considering the contradictory findings regarding supplemental oxygen therapy, more recent practice guidelines are diverging from the previous consensus that oxygen should be administered routinely in patients with cardiac disease. However, this new direction is also based on expert opinion rather than well-designed RCTs (7, (9) (10) (11) . The recommendations of different practice guidelines on oxygen therapy in hypoxemic and normoxemic patients with AHF are summarized in Table 2 . This topic has been studied in many other non-HF critically ill patient populations (12) . For example, the recent American Heart Association guideline on cardiopulmonary resuscitation in patients with cardiac arrest stated that "after restoring the spontaneous circulation, the inspired oxygen should be titrated to minimize the risk of hyperoxemia" (13) . studies (23) (24) (25) , it was not supported by others (26, 27) , and it seems to be a downstream impact of the oxidative stress. (38, 39) . Also, the aforementioned hyperoxia-related decrease in cardiac output seems to be gauged by a reduction in heart rate rather than a decrease in stroke volume (15). The heart rate reduction has been shown to be mediated by an increase in parasympathetic activity and not related to the sympathetic nervous system (16, (40) (41) (42) . The Central Illustration summarizes some potential mechanisms of effect for supplemental oxygen therapy in patients with cardiac diseases. These mechanisms are discussed in greater detail elsewhere (36, 39, 43) .
FUTURE DIRECTIONS: IS ADDITIONAL OXYGEN EFFECTIVE, COST EFFECTIVE, OR EVEN SAFE?
Oxygen therapy remains a cornerstone of AHF treatment in practice, but guidelines provide variable recommendations on its appropriate use, reflecting the lack of robust evidence on this "cornerstone"
therapy (2, 7, 8) . To produce a change in clinical practice given the long-standing and often fixed beliefs about the benefit of a "safe" therapy, studies beyond cohort studies must provide sufficient evidence to Oxygen Therapy in Acute Heart Failure 3. an RCT with center-based cluster randomization to usual care versus health care personnel titration to a set target (e.g., >92%) using face mask or nasal cannula; and 4. an RCT with patient-level randomization to automated oxygen titration system set at 2 separate targets (e.g., 90% vs. 96%). 
